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Homology-dependent RNA silencing occurs in many eukaryotic
cells. We reported recently that nodaviral infection triggers an RNA
silencing-based antiviral response (RSAR) in Drosophila, which is
capable of a rapid virus clearance in the absence of expression of
a virus-encoded suppressor. Here, we present further evidence to
show that the Drosophila RSAR is mediated by the RNA interfer-
ence (RNAi) pathway, as the viral suppressor of RSAR inhibits
experimental RNAi initiated by exogenous double-stranded RNA
and RSAR requires the RNAi machinery. We demonstrate that RNAi
also functions as a natural antiviral immunity in mosquito cells. We
further show that vaccinia virus and human influenza A, B, and C
viruses each encode an essential protein that suppresses RSAR in
Drosophila. The vaccinia and influenza viral suppressors, E3L and
NS1, are distinct double-stranded RNA-binding proteins and es-
sential for pathogenesis by inhibiting the mammalian IFN-regu-
lated innate antiviral response. We found that the double-stranded
RNA-binding domain of NS1, implicated in innate immunity sup-
pression, is both essential and sufficient for RSAR suppression.
These findings provide evidence that mammalian virus proteins
can inhibit RNA silencing, implicating this mechanism as a nucleic
acid-based antiviral immunity in mammalian cells.
RNA silencing is a unique RNA-guided gene regulatorymechanism that operates in a wide range of eukaryotic
organisms from plants to mammals (1). A feature common to all
RNA silencing processes is the production of 21- to 26-nt small
RNAs from structured or double-stranded RNA (dsRNA) by the
endoribonuclease Dicer (2–6). These small interfering RNAs
(siRNAs) control the specificity of RNA silencing in a homol-
ogy-dependent manner by means of an RNA-induced silencing
complex (RISC), of which Argonaute-2 (AGO2) is an essential
protein component (1, 7, 8). RNA silencing in fungi, plants, and
worms involves a cellular RNA-dependent RNA polymerase
(RdRP); however, the multiple-turnover RISC may mediate
RNA silencing in absence of a cellular RdRP in Drosophila and
mammalian cells (1, 9–11).
We reported recently that infection of cultured Drosophila
cells with the plus-strand RNA Nodavirus f lock house virus
(FHV), triggers specific silencing of FHV RNAs that is associ-
ated with accumulation of 22-nt siRNAs (12). Silencing of the
replicating viral RNAs is RISC-dependent and sensitive to
inhibition by the FHV B2 protein, as shown by the observation
that B2 is essential for FHV infection of WT Drosophila cells but
dispensable in cells depleted for AGO2 (12). These findings
provided an example indicating an antiviral role for RNA
silencing in the animal kingdom (12, 13), as has been established
in higher plants (14–18).
In this article, we report that specific RNA silencing was
induced in mosquito cells in response to viral RNA replication
and show that this mosquito antiviral immunity is RISC-
dependent and sensitive to suppression by the B2 protein
encoded by either FHV or nodamura virus (NoV). We demon-
strate that NoV RNA replication also triggered specific silencing
of viral RNAs in Drosophila cells, as has been found after
challenge with FHV (12), and we provide further evidence that
the RNA silencing-based antiviral response (RSAR) in Drosoph-
ila is mediated by the RNA interference (RNAi) pathway. We
established a functional screen in cultured Drosophila cells based
on the nodaviral RNA silencing system and found that the IFN
antagonist proteins encoded by four mammalian viruses are
suppressors of the Drosophila RSAR. Our results provide ex-
perimental evidence indicating a natural antiviral role for RNA
silencing in mammals. A possible role of RNA silencing in the
IFN-regulated mammalian innate immunity is discussed.
Materials and Methods
Plasmids. pFR1 and pFR1-B2, encoding the WT and B2-
knockout mutant of FHV RNA1, have been described (12).
pFR1gfp was obtained by replacing the NcoI–SacI fragment
(corresponding to nucleotides 2,802–3,001 of RNA1) of pFR1
with the coding sequence for GFP. Full-length cDNA of NoV
RNA1 and the mutant 1 (B2B1), together with a hepatitis
delta virus ribozyme at the 3 end (19), were cloned immediately
downstream of the CuSO4-inducible metallothionein promoter
in pMTV5-HisA vector (Invitrogen) to give pNR1 and pNR1-
B2 as described (12). pONR1 and pONR1-B2 contained the
same cDNA sequences downstream of the constitutive OplE2
promoter in pIZ vector (Invitrogen). The coding sequence for
either fB2 or nB2 was cloned into pIZ vector for expression in
mosquito cells. The coding sequence for nB2, p19, E3L (from
vaccinia virus Western Reserve strain), ANS1 (from influenza
AWSN33 virus), BNS1 (from influenza BYamagata73
virus), and CNS1 (from influenza CJHB66 virus) was cloned
in pMTV5-HisA for transient expression in S2 cells. pANS1
was digested with NcoI, end-filled, and religated to create
pNS1-A2. pNS1-A1 and pNS1-A3 were generated as described
(20, 21). pMTp19 was digested with Asp-718, end-filled, and
religated to create pMTp19fs, which led to translational termi-
nation after amino acid 24 of the 171-aa residue p19. pgfp and
pB2gfp were also constructed in pMTV5-HisA, and the trans-
lational fusion between B2 and GFP in pB2gfp was separated by
a BamHI site.
siRNAs and dsRNAs. siRNAs were synthesized by Qiagen (Valen-
cia, CA), targeting nucleotides 1,695–1,717 (aatgcagtgcgtggag-
gttgttt) and 3,293–3,315 (aacccaagatttgctgcgtgatt) of Drosophila
AGO2, and nucleotides 1,717–1,737 (aagcgcaagatcctcgacctg)
and 3,120–2,142 (aatcatcgacacggttaataatt) of Anopheles gambiae
AGO2. An siRNA (aattatcgatgagcgtggtggtt) targeting nucleo-
tides 819–841 of the lacZ mRNA was used as a control.
Abbreviations: AGO2, Argonaute-2; dsRNA, double-stranded RNA; FHV, flock house virus;
NoV, nodamura virus; RdRP, RNA-dependent RNA polymerase; RISC, RNA-induced silencing
complex; RNAi, RNA interference; RSAR, RNA silencing-based antiviral response; siRNA,
small interfering RNA.
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Typically, a plasmid DNA (0.3 g) was mixed with siRNA (0.3
g) or a dsRNA of 500 bp (0.3 g) in cotransfection experi-
ments. dsRNAs corresponding to the PAZ and PIWI domains of
both A. gambiae AGO1 and AGO2 were synthesized in vitro as
described for Drosophila (12).
Cell Culture, Transfection, and Analyses. Both Drosophila S2 cells
and A. gambiae 4a-2s4 cells were cultured at 27°C in Schneider’s
insect medium (Sigma) supplemented with FBS. The Effectene
transfection reagent (Qiagen) and CellFectin reagent (Invitro-
gen) were used for transfection of the fruit f ly and mosquito
cells, respectively, according to the manufacturer’s instructions.
RNA transcription from pMT-derived plasmids was induced by
overnight incubation with CuSO4 at 0.5 mM. No induction was
necessary for transfection with pIZ-derived plasmids in the
mosquito cells. Two days after induction in Drosophila cells or 3
days after transfection in mosquito cells, total RNA was ex-
tracted by using the Trizol reagent, and 10 g from each sample
was fractionated and analyzed by Northern blot hybridization as
described (22). DNA fragments corresponding to the B2 coding
sequence of either FHV or NoV were labeled as probes by using
the Rediprime II random prime labeling system (Amersham
Biosciences). RNA quantification from Northern blot hybrid-
izations was carried out with a Molecular Imager FX Phosphor-
Imager (Bio-Rad).
Electrophoretic Mobility-Shift Assay. The assay was carried out as
described (23). Briefly, 0.4 M of GST fusion protein, NS1 or
NS1-A1, was incubated on ice for 30 min in 20 l of binding
buffer with 32P-radiolabeled (10,000 cpm, 1 nM) 76-nt dsRNA,
or 21-nt siRNA that was produced with the Silencer siRNA
construction kit (Ambion, Austin, TX) according to the manu-
facturer’s instructions. siRNA was targeted at nucleotides 123–
144 of eGFP (aagctgaccctgaagttcatc). The protein–RNA com-
plexes were resolved in an 8% nondenaturing polyacrylamide gel
run at 4°C for 4 h at 150 V in 45 mM Tris-borate1 mM EDTA.
Results
B2 of FHV Is a Suppressor of RNAi. The biochemical framework of
the core RNA silencing pathway is based mostly on the
experimental induction of RNA silencing by exogenous
dsRNA, commonly referred to as RNAi (1, 24). Thus, we first
investigated whether B2 of FHV, known to inhibit RNA
silencing induced by viral RNA replication, also suppresses
RNAi. To this end, Drosophila cells were transfected with a
plasmid encoding either GFP or B2 fused with GFP (B2-GFP)
under the control of an inducible promoter, and 1 day after
induction of expression of GFP or B2-GFP, dsRNA targeting
the GFP coding sequence was introduced (Fig. 1B). B2-GFP
remained active in suppressing virus RNA silencing as co-
transfection with either pB2-GFP or pB2 rescued the in vivo
accumulation of the self-replicating FHV RNA1 mutant car-
rying an untranslatable B2, called FR1-B2 (Fig. 1 A, lanes 4
and 5). Suppression of AGO2 expression by the specific
dsRNA also rescued the accumulation of FR1-B2 RNAs (Fig.
1 A, lane 6), as expected (12). In the GFP RNAi assay (Fig. 1B),
targeting of the B2-GFP mRNA by RNAi occurred in cells that
were also expressing B2-GFP. Northern blot hybridizations
found that accumulation of GFP mRNA was significantly
reduced 2 days after GFP dsRNA was introduced as compared
with treatment with lacZ dsRNA (compare lanes 3 and 4 in Fig.
1B), indicating an effective RNAi against GFP mRNA by this
sequential transfection protocol. However, no obvious differ-
ence in the accumulation of B2-GFP mRNA was observed
between cells treated with either GFP or lacZ dsRNA (com-
pare lanes 5 and 6 in Fig. 1B). Thus, the specific degradation
of mRNA targeted by a homologous dsRNA did not occur in
Fig. 1. B2 of FHV suppresses RNA silencing induced by a replicating virus RNA (A) or dsRNA (B) in cultured fruit fly cells. (A) Cells were transfected with buffer
(Mock), pFR1, pFR1-B2 alone or with pB2gfp, pfB2, or dsRNA of AGO2, as indicated at the top of each lane. Total RNA was extracted 2 days after induction for
Northern blot analysis by a probe specific to the B2 coding region of FHV. (B) Cells were either cotransfected or sequentially transfected with a protein-expressing
plasmid (pB2gfp or pgfp) and a dsRNA (targets GFP or lacZ mRNA as a control). Total RNA was extracted 2 days after the last transfection and analyzed by Northern
blot hybridization with a probe specific to the GFP mRNA. RNA species corresponding to FHV RNAs 1 and 3, mRNA of B2-GFP, and GFP were indicated. Note that
the mRNA from pB2 comigrated with RNA3 (A, lane 5). Equal RNA loading was shown by methylene blue staining of rRNA (Lower).












































Drosophila cells expressing the B2 fusion protein, establishing
FHV B2 as a viral suppressor of RNAi in an animal system.
When GFP dsRNA was cotransfected with pB2-GFP, how-
ever, B2-GFP mRNA was effectively destroyed by RNAi (com-
pare lanes 7 and 8 in Fig. 1B). Thus, RNAi suppression requires
B2 expression before dsRNA is introduced into cells to initiate
RNAi, suggesting that B2 suppression may occur before the
production or RISC loading of siRNAs. Collectively, our data
show that RNA silencing triggered by either dsRNA or viral
RNA replication not only is AGO2-dependent, but also is
sensitive to B2 suppression, providing compelling evidence that
the RNA silencing antiviral immunity detected in Drosophila
cells is mediated by the RNAi pathway.
NoV Induces and Inhibits RNA Silencing in Drosophila. We next
investigated whether the RNA silencing antiviral response is
elicited when Drosophila cells are challenged with another
virus. NoV is the only member of the Alphanodavirus genus
that can lethally infect both insects and mammals. However,
the sequence identity between the encoded proteins of NoV
and FHV is either low (44% for the viral RdRP) or minimal
(19% for B2) (25). We constructed a full-length NoV RNA1
cDNA clone (pNR1) encoding a self-replicating RNA, essen-
tially as described (12) for FHV. After transfection into the
Drosophila S2 cells and transcriptional induction of the viral
cDNA, pNR1 directed RNA1 self-replication and transcrip-
tion of RNA3, the subgenomic mRNA for B2 (Fig. 2, lane 1).
Also as expected (19), a point mutation, as in NR1-B1, that
abolished translation of the overlapping B1 ORF from RNA3,
corresponding to the C-terminal portion of the viral RdRP,
had no effect on the accumulation of either RNA1 or RNA3
(Fig. 2, lane 2). However, a B2-knockout mutant, referred to
as NR1-B2, was hardly detectable in transfected Drosophila
cells by Northern blot hybridizations (Fig. 2, lane 3). NR1-B2
contained point mutations that prevented B2 translation but
did not change any amino acid in the 1 reading frame that
codes for RdRP, as described (19). The defect of NR1-B2
accumulation in WT Drosophila cells was complemented in
trans by cotransfection of a plasmid expressing the NoV B2
protein (nB2), indicating that nB2 is required for NoV RNA
accumulation (Fig. 2, lane 6).
Several lines of evidence indicate that NoV RNAs were
targeted for silencing by the AGO2-dependent RNAi pathway in
Drosophila cells and that nB2 suppressed the RNAi antiviral
response to ensure successful NoV RNA replication and tran-
scription. First, the FHV B2 protein (fB2), shown to suppress
RNAi (12), rescued accumulation of NR1-B2 in Drosophila
cells (Fig. 2, lane 5). Second, depleting RISC by either dsRNA
or siRNA targeting AGO2 efficiently rescued accumulation of
NR1-B2 (Fig. 2, lanes 4 and 7). Such a rescue was not observed
by cotransfection with an unrelated lacZ siRNA (Fig. 2, lane 8)
or dsRNA (data not shown). These results indicate that rescue
of NR1-B2 by cotransfection of dsRNA and siRNA targeting
AGO2 is caused by a specific AGO2 depletion, rather than a
nonspecific effect of dsRNA. Similar specific rescue of FR1-B2
in Drosophila cells by either the dsRNA or siRNA targeting
AGO2, but not by the dsRNA and siRNA targeting lacZ, was
also observed (see also Fig. 5, lanes 14–17). In addition, nB2
suppressed RNA silencing targeted against (i) FR1-B2 in
transfected Drosophila cells (see Fig. 5, lane 4) and (ii) a GFP
transgene in transgenic plants (data not shown), as has been
found for fB2 (12).
Remarkably, we found an effective suppression of RSAR
targeting FR1-B2 in Drosophila by the tombusvirus 19-kDa
protein (p19) (26, 27), but not after it was truncated (see Fig. 5,
lanes 12 and 13). This finding demonstrates cross-kingdom
suppression of RNA silencing in an animal system by a plant viral
suppressor. Together with the observations that the B2 proteins
encoded by two animal nodaviruses suppress RNA silencing in
both Drosophila and tobacco plants (12), our results show that
the RSAR mechanism is conserved between the plant and
animal kingdoms.
RNA Silencing Is a Natural Antiviral Response in Mosquito Cells.
Because the genome of the mosquito A. gambiae, which transmits
both malaria and viruses (28), encodes a functional RNAi
pathway similar to Drosophila (29–31), we investigated whether
RNAi also protects A. gambiae against NoV. Self-replication of
NoV RNA1 and transcription of RNA3 were detected (Fig. 3,
lane 1) in cells after transfection with pONR1, which contained
the NoV RNA1 cDNA under the control of the OplE2 promoter.
Fig. 2. Induction and suppression of RNA silencing by NoV. Fruit fly cells were
transfected with pNR1, pNR1-B1 or pNR1-B2 alone or with a B2-expressing
plasmid (fB2 or nB2), and either dsRNA or siRNA specific for AGO2. An siRNA
targeting lacZ mRNA was used as a control. Total RNA was extracted 2 days
after induction for Northern blot analysis by a probe specific to the B2 coding
region of NoV.
Fig. 3. An RNA-based antiviral immunity in mosquito cells. A. gambiae
4a-2s4 cells were transfected with pONR1, pONR1-B2 alone or with a pIZ-
based plasmid coding for fB2 or nB2, plus dsRNA targeting the PAZ domain of
A. gambiae AGO1 or AGO2. A lacZ dsRNA was used as a control. An identical
blot was probed for the accumulation of AGO2 mRNA with DNA correspond-
ing to the C-terminal PIWI domain of A. gambiae AGO2. RNA was extracted
and analyzed as for Fig. 2.




































pNR1 failed to initiate RNA replication in A. gambiae cells (data
not shown), possibly because of a lack of transcriptional induc-
tion. Neither RNA1 replication nor RNA3 transcription was
detected in A. gambiae cells transfected with pONR1-B2 (Fig.
3, lane 3), which encoded the B2-knockout mutant of NoV
RNA1. However, the defect was rescued by cotransfection with
either a plasmid expressing a B2 (Fig. 3, lanes 7 and 8) or a
dsRNA corresponding to mRNA of the A. gambiae AGO2 (Fig.
3, lane 6). The rescue of ONR1-B2 was also observed by
cotransfection with an siRNA targeting AGO2, although with an
efficiency 50% lower than the long dsRNA (data not shown).
ONR1-B2 rescue by AGO2 depletion was specific as cotrans-
fection with dsRNA to neither lacZ (Fig. 3, lane 4) nor AGO1
mRNA (Fig. 3, lane 5) was effective. Thus, as found in Dro-
sophila, a self-replicative NoV RNA also triggered the RNAi
antiviral response in A. gambiae cells, which is both AGO2
dependent and sensitive to B2 suppression, establishing this
immunity pathway in two different insect cell lines. This finding
opens up the possibility of targeting this pathway to prevent
transmission of mosquito-borne human viral diseases such as
dengue.
A Cell-Based Screen for Identifying Animal RNA Silencing Suppressors.
To facilitate screening for new animal RNAi suppressors, we
fused the coding sequence of GFP in-frame with the start of
the B2 ORF of FHV RNA1 to yield pFR1gfp (Fig. 4A).
pFR1gfp was essentially a B2-knockout mutant carrying a
visual marker because only the first 23 aa of the 106-aa residue
fB2 were translated in the fusion protein. Indeed, GFP cells
were not visible after pFR1gfp was transfected alone (Fig. 4B
Upper Left) but became abundant when it was cotransfected
with a B2-expressing plasmid (Fig. 4B Upper Right). GFP
expression was detected also when pFR1gfp was cotransfected
with the AGO2 dsRNA (data not shown). Replication and
accumulation of FR1gfp in S2 cells cotransfected with either
the AGO2 dsRNA or the fB2-expressing plasmid were con-
firmed by Northern blot detection of both positive- and
negative-strand viral RNAs (data not shown). Thus, FR1gfp
was defective in suppressing RSAR in Drosophila cells as was
FR1-B2. Importantly, B2 suppression of the Drosophila RNA
silencing response targeting either FR1gfp or FR1-B2 did not
require prior B2 expression, which was found to be necessary
for RNA silencing induced by dsRNA (Fig. 1B). This finding
is consistent with the natural situation in which the expression
of B2 after viral RNA replication but early in infection is
sufficient to allow productive FHV infection (12) and estab-
lishes an easy cell-based assay for the identification of animal
RNAi suppressors, simply by detection of GFP after cotrans-
fection of pFR1gfp with a plasmid expressing a candidate
protein.
Identification of Mammalian Viral Proteins That Suppress the Dro-
sophila RSAR. The nodaviral silencing system established in
Drosophila cells was used in a search for mammalian viral
suppressors of RNA silencing because the RNAi machinery is
highly conserved between Drosophila and humans and the
available mammalian RNA silencing system induced by siR-
NAs (32) will not be able to identify suppressors that act
upstream of siRNA production. NS1 encoded by inf luenza A
virus was among those first selected because it is encoded by
an overlapping gene and inf luences virulence and virus accu-
mulation but is not essential for viral replication (33), which
are common features of many known viral silencing suppres-
sors such as the nodaviral B2 and plant viral 2b proteins (12,
16, 34). We found that NS1 protein expressed from a cotrans-
fected plasmid indeed rescued GFP expression from pFR1gfp
in Drosophila cells (Fig. 4B Lower Right). GFP expression was
also observed in cells cotransfected with a plasmid expressing
E3L of vaccinia virus (Fig. 4B Lower Left), which shares key
functional features with NS1 (35, 36). The RSAR suppressor
activity of both NS1 and E3L was confirmed further by the
rescue of FR1-B2 in Drosophila cells, leading to detection of
both the genomic (RNA1) and subgenomic (RNA3) RNAs of
FHV, as illustrated by Northern blot hybridization (Fig. 5,
lanes 5 and 8). The cotransfection experiments also revealed
that the NS1 proteins encoded by the related inf luenza B and
C viruses were also suppressors of RSAR (Fig. 5, lanes 6 and
7). Efficient rescue of NR1-B2 by these vertebrate viral
suppressors was also observed in cotransfected Drosophila
cells (W.-X.L. and S.-W.D., unpublished observations). These
experiments identify mammalian viral proteins capable of
suppressing RNA silencing in an animal system and indicate
that this activity is an evolutionarily conserved function of NS1
encoded by the three inf luenza virus genera in the Orthomyxo-
viridae family.
NS1 Suppression of RNAi Requires the N-Terminal dsRNA-Binding
Domain. Both NS1 and E3L bind dsRNA in vitro, although each
involves a distinct protein structure (37). E3L contains the
dsRNA-binding motif found in many cellular proteins and the
reovirus 3 protein, which was recently found to suppress
transgene RNA silencing in plants with a coinfiltration protocol
(38). Further, the NS1 proteins encoded by influenza A, B, and
C viruses, designated ANS1, BNS1, and CNS1, share few
sequence similarities beyond the N-terminal dsRNA-binding
domain (39). To analyze the role of the dsRNA-binding domain
Fig. 4. Suppression of the RNAi antiviral response visualized by GFP expres-
sion. (A) Genome organization and expression of FHV RNA1 and R1gfp. RNA1
encodes protein A, the catalytic subunit of the viral RdRP, and directs tran-
scription of RNA3, mRNA for protein B2. Nucleotides 2,802–3,001 of RNA1 as
encoded in pFR1 were replaced with the coding sequence for enhanced GFP
(eGFP) to give pFR1gfp so that eGFP was translated from a chimeric RNA3 as
a fusion protein with the N terminus of B2. (B) Detection of GFP expression in
fruit fly cells from a FHV RNA1 mutant defective in silencing suppression. Cells
were transfected with pFR1gfp alone or with a plasmid expressing fB2, E3L, or
NS1A and photographed 2 days after induction.












































of NS1 in RSAR suppression, two mutants of ANS1 were
created. The first contained alanine substitution of Arg-38 and
Lys-41 (designated NS1-A1), which are essential for dsRNA
binding, whereas the second contained only the N-terminal
fragment (82 aa) of ANS1 (designated NS1-A2), which pos-
sesses all of the in vitro RNA-binding properties of the full-length
230-aa protein (39).
We found that the R38AK41A mutant (NS1-A1) was
unable to rescue FR1-B2 in transfected Drosophila cells (Fig.
5, lane 9). In contrast, the N-terminal fragment (NS1-A2)
retained the activity of ANS1 to rescue FR1-B2 in trans-
fected cells (Fig. 5, lane 10). These results indicate that the
N-terminal dsRNA-binding domain of ANS1 is both essential
and sufficient in the suppression of RSAR in the invertebrate
animal cells. Interestingly, ANS1, but not NS1-A1, was found
to bind synthetic siRNA (Fig. 6). This finding indicates that
NS1 suppression of RSAR may require siRNA binding, as
proposed for p19 (27), and is unlikely caused by a simple
dsRNA sequestration, the latter of which is also supported by
the failure to rescue FR1-B2 in Drosophila cells by cotrans-
fection with plasmids that code for any of the five cellular
dsRNA-binding motif-containing Drosophila proteins (X.
Wang, F.L., and S.-W.D., unpublished data).
By comparison, NS1-A2 was weaker than WT ANS1 in
RSAR suppression (Fig. 5, compare lanes 8 and 10). Intriguingly,
NS1-A2 exhibited a significantly reduced activity in preventing
RNA silencing that targeted the genomic RNA1, similar to that
of the plant virus protein p19 (Fig. 5, compare lane 8 with lanes
10 and 12). Furthermore, we found that a single Asp-to-Glu
mutation at position 92 of ANS1 enhanced the rescue efficiency
as compared to WT ANS1, indicated by an 100% increase in
the accumulation of RNA1 observed in two independent exper-
iments (Fig. 5, compare lanes 8 and 11). Position 92 is located
near the known RNA-binding domain, and the D92E mutation
was associated with the virulence of the lethal H5N1 influenza
A virus isolate transmitted to humans in 1997 (21). These
findings indicate that the amino acid sequence of NS1 that is C
terminal to the core RNA-binding domain is able to modulate
the activity of NS1 in RNAi suppression.
Discussion
Members of Orthomyxoviridae have segmented negative-strand
RNA genomes, whereas vaccinia virus, which is used as the
vaccine for smallpox, contains a double-stranded DNA genome.
Our work shows that these diverse mammalian viruses encode
proteins that are potent suppressors of the Drosophila RSAR. It
is known that mammals encode a functional RNA silencing
pathway (1) and that NS1 and E3L are both essential for viral
pathogenesis in mammalian hosts (40). Thus, we postulate that
RNA silencing is a major antiviral response in mammals and that
encoding a suppressor of RNAi is an essential feature of
mammalian viruses, as has been established for viruses that
infect plants and invertebrates (refs. 12, 16, 17, and 41 and this
work).
Our hypothesis is supported by three additional lines of
evidence. First, human cells are equipped with an RNAi ma-
chinery, including Dicer and RISC, that is most closely related
to that found in Drosophila (5, 10, 42–44). Second, recent work
Fig. 5. Suppression of the RNAi antiviral response by E3L and NS1 proteins. Fruit fly cells were transfected with a pFR1-derived plasmid plus either another
plasmid expressing a viral RNAi suppressor (fB2, nB2, E3L, CNS1, BNS1, ANS1, or p19) or a dsRNAsiRNA (to mRNA of AGO2 or lacZ). NS1-A1 contained the
R38AK41A mutation, NS1-A2 corresponded to the N-terminal 82 aa of WT ANS1, and NS1-A3 contained the D92E mutation. p19fs was a frameshift mutant
of p19 that terminates after the first 24 aa. RNA was extracted and analyzed as described for Fig. 2.
Fig. 6. Binding of GST-NS1 fusion protein to long and short dsRNAs in vitro.
GST (0.4 M, lanes 3 and 6), GST-NS1 (lanes 4 and 7), or GST-NS1-A1 (lanes 5 and
8) was incubated with 32P-radiolabeled dsRNA (Right) or siRNA (Center) before
the RNA–protein complexes were resolved in a nondenaturing polyacrylamide
gel electrophoresis. The positions of the free 76-nt dsRNA and the 21-nt siRNA
are indicated. The lower band in lanes 6–8 migrates in the same position as
T7-generated single-stranded RNA.




































found that replication of influenza A virus and of several
mammalian RNA and DNA viruses is effectively inhibited by
synthetic siRNAs, indicating that viral RNA can be targeted by
the RNAi machinery in mammalian cells (45, 46). Third, both
NS1 and E3L proteins are known to function in their mammalian
hosts as inhibitors of the innate antiviral response regulated by
the IFN system (40), a first line of vertebrate defense against
virus infections. Notably, the dsRNA-binding domains of NS1
and E3L are also required to inhibit the innate antiviral immu-
nity (20, 35), as found for NS1 suppression of the Drosophila
RSAR (Fig. 5). Thus, our observations are more consistent with
an antiviral role for RNA silencing in mammals, most likely as
part of the mammalian innate antiviral immunity. However, it
cannot be ruled out at present that the innate antiviral immunity
targeted by NS1 in mammalian cells is unrelated to RNA
silencing; for example, NS1 may target an unrelated or shared
factor in the two independent mechanisms. In this regard, it is
of interest to consider that, similar to the innate antiviral
immunity, RSAR is rapid, effective in single cells, and highly
specific, and previous studies have indicated the existence of
alternative antiviral effector pathways in addition to those
mediated by protein kinase PKR, RNase L, and Mx proteins
(35, 47).
Important questions that remain to be addressed are whether
viral infection indeed triggers specific RNA silencing in verte-
brates, whether this antiviral response is regulated by the IFN
system, and whether other known viral suppressors of RSAR are
also effective IFN antagonists. Such a positive effect on RSAR
by IFN could occur before the production of viral siRNAs in the
vertebrate RSAR pathway because RNA silencing initiated by
synthetic siRNAs is independent of the IFN system (48). In any
case, discovery of RNAi suppressor activity will facilitate screen-
ing for small molecule inhibitors of these essential mammalian
viral virulence factors, which may lead to new treatments of
human viral diseases.
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